BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026
BioNTech will present 16 abstracts across ten tumor types at the ESMO 2026 Congress in Madrid, October 23-27, 2026, headlined by late-breaking oral data for pumitamig plus docetaxel in second-line metastatic NSCLC. First global Phase 2 results for the novel-novel combination of pumitamig with the B7-H3 ADC elfetabart drozuntecan showed encouraging preliminary antitumor activity across multiple advanced solid tumors with a manageable safety profile. Pumitamig, a PD-L1xVEGF-A bispecific being co-developed with Bristol Myers Squibb, is positioned as a potential combination backbone across tumor types, including brain-metastasis settings in SCLC and TNBC.
Key figures
- Abstract count
- 16
- Tumor types covered
- 10
- Ongoing phase3 trials
- 13
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.